Sanofi SA (NASDAQ:SNY)
| 47.80 BATS BZX Real-Time Price As of 11:07am ET |  -0.33 / -0.69%Today’s Change | 44.76 Today|||52-Week Range 54.26 | -1.63% Year-to-Date |
Latest SNY News | Press Releases
| 3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30% 5:55am / MotleyFool.com - Paid Partner Content | Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe Sep 20 / Zacks.com - Paid Partner Content |
| Bristol-Myers Reportedly Most Likely Buyer of Acceleron Pharma Sep 27 / GuruFocus News - Paid Partner Content | Here's Why Moderna's Stock Could Crash Before the End of 2021 Sep 19 / MotleyFool.com - Paid Partner Content |
| Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids Sep 27 / Zacks.com - Paid Partner Content | 5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch Sep 18 / MotleyFool.com - Paid Partner Content |
| 3 Top Biotech Stocks to Buy for the Long Haul Sep 27 / MotleyFool.com - Paid Partner Content | AbbVie's Pain Is Sanofi's and Regeneron's Gain Sep 18 / MotleyFool.com - Paid Partner Content |
| Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis Sep 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 48.13 |
| Today’s open | 48.20 |
| Day’s range | 47.69 - 48.22 |
| Volume | 27,410 |
| Average volume (3 months) | 1,838,980 |
| Market cap | $120.1B |
Data as of 11:07am ET, 09/28/2021
Growth & Valuation
| Earnings growth (last year) | +330.16% |
| Earnings growth (this year) | -95.90% |
| Earnings growth (next 5 years) | +6.40% |
| Revenue growth (last year) | +1.61% |
| P/E ratio | 17.8 |
| Price/Sales | 2.98 |
| Price/Book | 1.56 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BMYBristol-Myers Squibb | -0.29 | -0.48% |
| GSKGlaxoSmithKline | -0.50 | -1.30% |
| ZTSZoetis Inc | -5.94 | -3.00% |
| ---- |
Data as of 11:08am ET, 09/28/2021
Financials
| Last reporting date | -- |
| EPS forecast (this quarter) | $0.70 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $14.0B |
| Net profit margin | 34.17% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Paris, Ile-de-france |
Forecasts
